Evenity (Romosozumab) Cost in Nevada 2026: Pricing, Insurance, and Savings

Romosozumab (brand name Evenity, marketed by Amgen and UCB) is a monoclonal antibody biologic approved by the FDA to treat osteoporosis in postmenopausal women at high fracture risk. It is given as two 105 mg subcutaneous injections once a month for 12 months, then followed by an antiresorptive drug such as denosumab or a bisphosphonate to preserve the bone density gained during treatment.

There is no single stable "Evenity price" that applies to every Nevada resident. What a person actually pays depends on whether they are cash-pay, on Medicare Part B, on a commercial plan, or on Medicaid, and insurer formularies, copay-card terms, and state Medicaid coverage decisions change from year to year. The more useful question for a Nevada patient is not "what does Evenity cost" but "which of the cost variables below apply to my coverage, and have I confirmed the current figure directly rather than relying on a published number that may be out of date."

Romosozumab (Evenity) is FDA-approved for postmenopausal women at high risk of fracture and is given as two 105 mg subcutaneous injections monthly for 12 months, after which an antiresorptive agent must be started to maintain bone density gains. Its FDA label carries a boxed warning against starting the drug in patients who have had a myocardial infarction or stroke within the prior 12 months. Cash price, insurance classification, and Nevada Medicaid coverage status for Evenity are all date-sensitive and should be confirmed directly with the pharmacy, insurer, and Nevada Medicaid program before a patient begins the 12-dose course, rather than assumed from a previously published figure.

What is established versus what needs verification

Established from the FDA label and accountable clinical bodies:

• Romosozumab is FDA-approved for postmenopausal women with osteoporosis at high fracture risk, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of or intolerance to other osteoporosis therapies (FDA label).
• The regimen is 12 monthly doses (two 105 mg subcutaneous injections per dose), followed by transition to an antiresorptive agent.
• The FDA label carries a boxed warning against initiating romosozumab in patients with myocardial infarction or stroke within the preceding year.
• Romosozumab is a biologic regulated under the Public Health Service Act rather than the compounding provisions of the Food, Drug, and Cosmetic Act, so it cannot legally be produced by a traditional 503A compounding pharmacy (FDA compounding Q&A).
• A 2020 clinical practice guideline for postmenopausal osteoporosis from a major endocrine professional society discusses anabolic-first therapy, including romosozumab, for patients at very high fracture risk.

Plausible but requiring current confirmation (these are the parts that change year to year and were not independently verified against a live source for this draft):

• The exact manufacturer list price and cash-pay price per dose in Nevada.
• Whether Nevada Medicaid currently excludes Evenity from its formulary, and under fee-for-service versus which managed care organizations.
• The specific prior authorization criteria and step-therapy requirements used by individual Nevada commercial plans.
• The current annual maximum and eligibility terms of the Amgen/UCB copay savings card and the Amgen Safety Net Foundation.
• Exact Medicare Part B coinsurance dollar amounts, which depend on the current Part B deductible and any supplemental coverage.

Treat any specific dollar figure in older material, including prior versions of this page, as a starting point for a phone call, not a number to budget around without confirmation.

Cash-pay and list price

Evenity is priced as a specialty biologic with a monthly list price commonly reported in the low four figures per dose, and a full 12-dose course is a substantial cash-pay expense, generally well into five figures over the treatment period. Because specialty drug list prices are revised periodically and Nevada specialty pharmacies may price at or near list, a patient planning to pay cash should request a written quote or predetermination letter from the dispensing pharmacy or infusing practice before starting treatment, rather than relying on a previously published per-dose figure.

Nevada Medicaid coverage

Public reporting as of this draft's writing indicated that Nevada Medicaid, including fee-for-service and its managed care organizations, did not cover Evenity. This is a formulary decision that state Medicaid programs can revise, so it should be verified directly against Nevada Medicaid's current preferred drug list or by contacting the beneficiary's managed care plan before assuming coverage or lack of it.

If Evenity is not covered, options for a Nevada Medicaid beneficiary who meets clinical criteria typically include:

• Filing a formulary exception or fair hearing appeal, supported by documentation of fracture history, DXA T-scores, and prior bisphosphonate trial or intolerance.
• Applying to the Amgen Safety Net Foundation for possible free drug access (eligibility and current terms should be confirmed directly with the foundation).
• Discussing alternative anabolic agents such as teriparatide or abaloparatide with the prescriber, since Medicaid formulary status can differ by drug.

Commercial insurance and Medicare Part B

Most major commercial insurers cover Evenity with prior authorization, and typical criteria track the AACE/ACE guideline's definition of high or very high fracture risk: a DXA T-score at or below -2.5 at the spine or hip, or a history of fragility fracture, combined with documented trial of or contraindication to at least one oral bisphosphonate. Individual plans vary in step-therapy requirements and specialty tier placement, so prior authorization criteria should be confirmed with the specific plan rather than assumed uniform across insurers.

Medicare Part B covers Evenity under the medical benefit when administered in a provider's office, which is the typical administration setting, and standard Part B cost-sharing applies after the annual deductible unless the patient has supplemental (Medigap) coverage. The exact dollar amount a Nevada Medicare beneficiary owes per dose depends on the current Part B deductible and coinsurance structure for that year and should be confirmed with the plan.

Manufacturer savings programs

Amgen and UCB have offered a copay savings program for commercially insured patients and a separate patient assistance program (the Amgen Safety Net Foundation) for uninsured or underinsured patients who meet income criteria. These programs typically cannot be combined with Medicare, Medicaid, or other government insurance, and enrollment terms, annual maximums, and income thresholds are revised periodically. A patient or prescribing office should confirm current eligibility rules and dollar caps directly with the manufacturer program before relying on them for financial planning, and should note that some savings cards require annual re-enrollment, which matters for a 12-month treatment course that spans a calendar-year boundary.

Compounded romosozumab is not a real option

Romosozumab is a large, structurally complex monoclonal antibody produced in mammalian cell culture. Traditional 503A compounding pharmacies are equipped to compound small-molecule drugs from bulk ingredients, not to manufacture a glycoprotein biologic with the post-translational modifications required for it to function. The FDA's compounding guidance draws this line clearly: biologics licensed under the Public Health Service Act fall outside the scope of standard drug compounding (FDA compounding Q&A). A Nevada patient encountering an offer for "compounded romosozumab" at a lower price should treat that claim as a red flag rather than a savings opportunity.

Telehealth prescribing in Nevada

Nevada permits telehealth prescribing of specialty medications when conducted through a licensed physician and an appropriate synchronous encounter, consistent with general telehealth guidance for expanding access in areas with limited specialist availability (CDC telehealth resources). This can be useful for patients in rural Nevada counties where an in-person endocrinology or rheumatology visit would require significant travel. In practice, a telehealth visit can handle evaluation and prior authorization steps, but the patient will still need a local facility for DXA bone density scanning, and some patients will want an in-person visit for their first injection if they are not comfortable self-administering. Exact rules on what the Nevada State Board of Medical Examiners currently permits for controlled or specialty injectable prescribing via telehealth should be confirmed, since board policy can be updated.

The clinical evidence, and its limits

Romosozumab's FDA approval in 2019 rested on phase 3 trial data comparing it to placebo and to alendronate in postmenopausal women with osteoporosis. In general terms, the placebo-controlled trial reported a large relative reduction in new vertebral fractures within the first 12 months, and the head-to-head trial against alendronate reported reductions in vertebral, clinical, and hip fractures when romosozumab was followed by alendronate compared with alendronate alone. Because the specific citation identifiers referenced in earlier drafts of this material could not be independently confirmed against the primary literature for this revision, readers and clinicians should verify exact effect sizes against the original New England Journal of Medicine trial publications before citing precise numbers.

One safety finding is well established from the FDA label rather than secondary summaries: the pivotal head-to-head trial against alendronate showed a numerical imbalance in serious cardiovascular events favoring alendronate, and this is reflected in the FDA's boxed warning against starting romosozumab in patients with a myocardial infarction or stroke within the prior year. The absolute cardiovascular risk in a broader osteoporosis population without recent cardiovascular events is considered low by treating specialists, but this is a judgment to be made with the prescribing physician against the specific patient's cardiovascular history, not a general reassurance that applies to everyone.

A 2020 endocrine society clinical practice guideline supports romosozumab as a first-line option for patients at very high fracture risk, defined by criteria such as a recent fracture, fracture while on approved osteoporosis therapy, multiple fractures, a T-score below -3.0, or a high FRAX probability.

Who should not start romosozumab, and what a prescriber should confirm first

Before prescribing, a clinician should confirm the absence of myocardial infarction or stroke within the prior 12 months, address any calcium or vitamin D deficiency before starting treatment, and discuss the patient's ability to commit to 12 consecutive monthly injections followed immediately by an antiresorptive agent. Stopping romosozumab without transitioning to an antiresorptive is not a minor omission; bone density gains can reverse rapidly, which is why sequencing is considered part of the treatment rather than optional.

This article does not provide individualized dosing or treatment decisions. Any patient considering romosozumab should discuss their fracture risk, cardiovascular history, and coverage situation with their own prescriber.

Cost context relative to other osteoporosis drugs

Generic oral bisphosphonates such as alendronate are inexpensive by comparison, typically a small fraction of a specialty biologic's monthly cost. Denosumab (Prolia), teriparatide (Forteo, now also available generically), and abaloparatide (Tymlos) are the other commonly used higher-cost options, with teriparatide and abaloparatide typically given over a 24-month course compared with romosozumab's 12-month course. Exact current prices for each of these drugs change over time and should be confirmed at the pharmacy or with the plan rather than assumed from a fixed table, since specialty drug pricing is one of the more volatile figures in this space.

Verification checklist: what to confirm before relying on a Nevada Evenity cost figure

Use this checklist to separate facts that are stable (federal approval, dosing regimen, boxed warning) from facts that change and must be re-checked at the time of treatment.

Stable, unlikely to change without a formal regulatory or guideline update

• FDA-approved indication: postmenopausal women at high fracture risk (confirm via the current FDA label)
• Dosing regimen: two 105 mg subcutaneous injections monthly for 12 months
• Boxed warning: not recommended within 12 months of MI or stroke
• Biologic status precludes traditional 503A compounding
• Requirement to transition to an antiresorptive agent after the 12-dose course

Date-sensitive, must be re-verified before or at the start of treatment

• Current manufacturer list price and Nevada pharmacy cash-pay price
• Whether Nevada Medicaid (fee-for-service and the specific managed care organization) currently covers Evenity
• The specific commercial plan's prior authorization and step-therapy criteria for this drug
• Current Medicare Part B deductible and coinsurance amount for the plan year in question
• Whether a Medigap or supplemental plan will cover the Part B coinsurance
• Current terms, annual maximum, and re-enrollment requirements of the Amgen/UCB copay savings card
• Current income and enrollment criteria for the Amgen Safety Net Foundation
• Whether the prescribing physician's telehealth practice and the patient's location satisfy current Nevada Board of Medical Examiners telehealth prescribing rules

Who should confirm each item

• Price and formulary items: the dispensing specialty pharmacy or the insurer's member services line
• Medicaid coverage: Nevada Medicaid or the specific managed care organization directly
• Savings program terms: Amgen/UCB program administrator, not a general drug information website
• Clinical eligibility: the prescribing physician, referencing the patient's DXA results, fracture history, and cardiovascular history

Evidence boundary

Established: romosozumab's FDA-approved indication, dosing regimen, boxed warning, and its status as a biologic rather than a compoundable small molecule. Established at a guideline level: AACE/ACE's support for anabolic-first therapy, including romosozumab, in patients at very high fracture risk. Not established in this draft: the current exact cash price, the current Nevada Medicaid coverage decision, and the current terms of manufacturer savings programs, all of which require direct verification against a live source before a patient relies on them financially. Plausible but requiring primary-literature confirmation: the specific magnitude of fracture-risk reduction reported in the pivotal trials, which should be checked against the original trial publications rather than restated from a secondary summary.

Frequently asked questions

References

1. U.S. Food and Drug Administration. Evenity (romosozumab-aqqg) injection, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf
2. U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
3. Centers for Disease Control and Prevention. Telehealth resources. https://www.cdc.gov/telehealth/

This article is for general education and has not yet completed qualified medical review. It does not provide individualized diagnosis, dosing, or coverage determinations. Pricing, insurance, and Medicaid coverage details should be confirmed directly with the relevant payer or pharmacy before making treatment decisions.